

Title (en)

AGENT FOR TREATING URINARY INCONTINENCE INCLUDING STEM CELLS DERIVED FROM AMNIOTIC FLUID

Title (de)

MITTEL ZUR BEHANDLUNG VON HARNINKONTINENZ MIT STAMMZELLEN AUS FRUCHTWASSER

Title (fr)

AGENT POUR LE TRAITEMENT DE L'INCONTINENCE URINAIRE COMPRENANT DES CELLULES SOUCHE ISSUES DE LIQUIDE AMNIOTIQUE

Publication

EP 2679231 A4 20140813 (EN)

Application

EP 11859272 A 20110225

Priority

KR 2011001368 W 20110225

Abstract (en)

[origin: EP2679231A1] The present invention relates to a cell therapy product which is intended for regenerating a sphincter muscle and which contains stem cells derived from amniotic fluid, and more particularly, to a cell therapy product which is intended for regenerating the sphincter vesicae and which contains stem cells derived from amniotic fluid. Also, the cell therapy product of the present invention can be provided in the form of a formulation for administration through injection, said formulation being injected into a hydrogel complex to thereby improve the effects thereof. The composition including stem cells derived from amniotic fluid according to the present invention enables stem cells to be differentiated into muscles in the body of individual suffering from urinary incontinence by directly injecting the composition into the individual, thus effectively controlling urinary incontinence by recovering muscle functions. That is, the stem cells derived from amniotic fluid of the present invention are differentiated into muscles in-situ, and the differentiation into muscles can thus be achieved only with cells in order to recover muscle functions.

IPC 8 full level

A61K 35/50 (2006.01); **A61K 9/08** (2006.01); **A61K 35/12** (2006.01); **A61K 35/34** (2015.01); **A61P 13/00** (2006.01); **A61P 13/02** (2006.01);
A61P 13/10 (2006.01)

CPC (source: EP US)

A61K 9/0019 (2013.01 - EP US); **A61K 35/34** (2013.01 - EP US); **A61K 35/50** (2013.01 - EP US); **A61P 13/00** (2017.12 - EP);
A61P 13/02 (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61K 9/0034** (2013.01 - EP US)

Citation (search report)

- [XY] WO 03042405 A2 20030522 - CHILDRENS MEDICAL CENTER [US], et al
- [XY] WO 03014313 A2 20030220 - BRESAGEN LTD [AU], et al
- [XY] WO 2004044158 A2 20040527 - UNIV JOHNS HOPKINS [US], et al
- [Y] SIEVERT ET AL: "Tissue Engineering for the Lower Urinary Tract: A Review of a State of the Art Approach", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 52, no. 6, 21 November 2007 (2007-11-21), pages 1580 - 1589, XP022356359, ISSN: 0302-2838, DOI: 10.1016/J.EUROURO.2007.08.051
- [Y] EBERLI ET AL: "Muscle progenitor cells for the restoration of irreversibly damaged sphincter function: A pre-clinical study", JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, COLLEGE, CHICAGO, IL, US, vol. 205, no. 3, 1 September 2007 (2007-09-01), pages S106, XP022251539, ISSN: 1072-7515, DOI: 10.1016/J.JAMCOLLSURG.2007.06.263
- [XY] DE COPPI PAOLO ET AL: "Isolation of amniotic stem cell lines with potential for therapy", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 1, 1 January 2007 (2007-01-01), pages 100 - 106, XP009111361, ISSN: 1087-0156, DOI: 10.1038/NBT1274
- See references of WO 2012115298A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

EP 2679231 A1 20140101; EP 2679231 A4 20140813; US 2014050705 A1 20140220; WO 2012115298 A1 20120830

DOCDB simple family (application)

EP 11859272 A 20110225; KR 2011001368 W 20110225; US 201114001149 A 20110225